Headlines about Catalent (NYSE:CTLT) have trended somewhat positive on Monday, according to Accern. Accern identifies positive and negative press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Catalent earned a news impact score of 0.11 on Accern’s scale. Accern also gave news articles about the company an impact score of 46.8356359678421 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the media stories that may have effected Accern’s scoring:
Catalent (NYSE CTLT) traded up $0.15 during midday trading on Monday, reaching $40.62. The company’s stock had a trading volume of 1,123,903 shares, compared to its average volume of 974,977. The firm has a market cap of $5,380.00, a P/E ratio of 73.85, a P/E/G ratio of 2.32 and a beta of 1.47. The company has a debt-to-equity ratio of 2.66, a quick ratio of 1.78 and a current ratio of 2.22. Catalent has a 52 week low of $27.48 and a 52 week high of $47.87.
Catalent (NYSE:CTLT) last released its earnings results on Monday, February 5th. The company reported $0.41 earnings per share for the quarter, beating the consensus estimate of $0.31 by $0.10. The company had revenue of $606.30 million during the quarter, compared to the consensus estimate of $565.05 million. Catalent had a return on equity of 23.85% and a net margin of 3.03%. Catalent’s revenue was up 25.3% compared to the same quarter last year. During the same period in the previous year, the company posted $0.27 EPS. sell-side analysts anticipate that Catalent will post 1.53 EPS for the current fiscal year.
CTLT has been the topic of a number of recent analyst reports. BidaskClub lowered Catalent from a “buy” rating to a “hold” rating in a research report on Tuesday, November 14th. First Analysis assumed coverage on Catalent in a report on Friday, January 5th. They issued an “equal weight” rating on the stock. Zacks Investment Research upgraded Catalent from a “hold” rating to a “strong-buy” rating and set a $49.00 price objective on the stock in a report on Thursday, October 26th. Stephens lowered Catalent from an “overweight” rating to an “equal weight” rating in a report on Tuesday, February 6th. Finally, Bank of America set a $49.00 target price on Catalent and gave the stock a “buy” rating in a research note on Tuesday, February 6th. Six research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $45.60.
In related news, Director Uwe Roehrhoff acquired 7,500 shares of the firm’s stock in a transaction dated Tuesday, November 21st. The stock was acquired at an average price of $39.22 per share, for a total transaction of $294,150.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider John R. Chiminski sold 181,458 shares of the business’s stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $39.62, for a total value of $7,189,365.96. The disclosure for this sale can be found here. Company insiders own 1.70% of the company’s stock.
WARNING: This article was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/02/12/catalent-ctlt-getting-somewhat-positive-news-coverage-study-shows.html.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.